Insulin Lispro Research: What 1,391 Studies Show (2026) | RetatrutideCompare

Insulin Lispro — 1,391 studies indexed on PubMed. Rapid-acting prandial insulin; faster onset and shorter duration than regular insulin. Half-life: ~1 hour. FDA status: FDA-approved (1996).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Insulin Lispro?

There are approximately 1,391 studies indexed on PubMed that mention Insulin Lispro (Humalog, Admelog), based on a search last updated 2026-06-18.

Is Insulin Lispro FDA-approved?

FDA status: FDA-approved (1996).

How does Insulin Lispro work?

Rapid-acting prandial insulin; faster onset and shorter duration than regular insulin.

Reference facts

Also known as: Humalog, Admelog
Category: Hormonal & Pituitary
Mechanism of action: Rapid-acting prandial insulin; faster onset and shorter duration than regular insulin.
Targets: Insulin receptor
Indications under research or approved: Diabetes — prandial insulin
Regulatory status (reference entry): FDA-approved (1996)
Half-life: ~1 hour
Sequence: GIVEQCCTSICSLYQLENYCN
Sequence notes: Rapid-acting insulin: B-chain residues Pro28 and Lys29 swapped, reducing dimerization and accelerating absorption.
Molecular weight (Da): 5808
PDB accession: 1LPH
Originator / sponsor: Eli Lilly
First reported: 1994

Primary References

Humalog FDA label

Explore research articles about Insulin Lispro

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.